Necroptosis抑制剂及相关病症的研究进展  

Research Progress on Necroptosis Inhibitors and Related Disorders

作　　者：易宏婷 曾宣铭 张玉珂 颜蓉 雷彬 陈钟文[1] 刘华[1] Yi Hong-ting;Zeng Xuan-ming;Zhang Yu-ke;Yan Rong;Lei Bing;Chen Zhong-wen;Liu Hua(College of Pharmacy,Jiangxi University of Chinese Medicine,Nanchang Jiangxi 330004,China)

机构地区：[1]江西中医药大学药学院,江西南昌330004

出　　处：《江西化工》2023年第6期5-9,共5页Jiangxi Chemical Industry

基　　金：国家自然科学基金资助项目(81760706);江西省自然科学基金资助项目(2020BABL206146);江西省卫生与健康委员会科技计划项目(20191078);江西省教育厅科技计划重点项目(GJJ211208)。

摘　　要：Necroptosis是一类除细胞凋亡、细胞自噬之外的程序性细胞死亡方式,其在癌症治疗中可能触发和增强抗肿瘤免疫。TNF-α-RIPK1/3-MLKL是necroptosis最经典的信号通路。该文主要从TNF-α信号通路对一系列与necroptosis相关的疾病和necroptosis两类主要的受体相关蛋白抑制剂的研究现状进行综述,旨在从天然药物着手,通过中医药突破现有抑制剂的不足,为necroptosis的科学研究和临床治疗提供参考。Necroptosis has been shown to be another type of programmed cell death in addition to apoptosis and autophagy,which may trigger and enhance anti-tumor immunity in cancer therapy.TNF-α-RIPK1/3-MLKL is the most classical signaling pathway of necroptosis.In this paper,we mainly review the research status of a series of necroptosisrelated diseases and two types of receptor-associated protein inhibitors of necroptosis from TNF-αsignaling pathway,aiming to provide reference for scientific research and clinical treatment of necroptosis by starting from natural medicines and breaking through the inadequacy of existing inhibitors through Chinese medicine.

关 键 词：NECROPTOSIS RIPK1/3 MLKL 抑制剂 疾病 

分 类 号：R96[医药卫生—药理学] R914[医药卫生—药学]